Izvorni znanstveni članak
Gemcitabine in the First and Second-Line Chemotherapy of Advanced Non-Small Cell Lung Cancer
Branka Čučević
Denis Baričević
Marko Jakopović
Gzim Redžepi
Sažetak
Aim of this study was to estimate efficacy of gemcitabine in first and the second-line chemotherapy for patients with advanced non-small cell lung cancer (stage III and IV). In first-line chemotherapy, 120 patients were treated with different chemotherapy regimens. Fifty-nine patients were treated with gemcitabine/cisplatin (PG), 41 with cisplatin/ etoposide (PE) and 20 with mitomycin/ifosfamide/cisplatin (MIC). Forty patients, unsuccessfully treated with PE and MIC in first-line therapy were treated with PG (24 pts) and with best supportive care (BSC) (16 pts). In first-line therapy PG was superior to PE and MIC protocol (mean survival (MS) 10 vs. 7 vs. 8.5 months). Response rate (RR) for PG in first-line therapy was 46% and 21% in second-line. We showed also significantly better survival in patients treated with PG in second-line chemotherapy comparing to best supportive care (MS 9 vs. 5.5 months). Toxic side effects for combination PG was acceptable. This study confirmed that PG combination is safe and effective as first and second- line chemotherapy for patients with advanced non-small cell lung cancer.
Ključne riječi
gemcitabine; lung cancer; NSCLC; chemotherapy
Hrčak ID:
5274
URI
Datum izdavanja:
15.12.2005.
Posjeta: 1.906 *